Ptc Therapeutics (PTCT) Operating Leases (2019 - 2026)

Ptc Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $90.1 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 5.94% year-over-year to $90.1 million in Q1 2026; TTM through Mar 2026 was $90.1 million, a 5.94% increase from a year earlier, with the FY2025 full-year figure at $93.6 million, up 24.87% from the prior year.
• Operating Leases slipped to $90.1 million in Q1 2026 per PTCT's latest filing, from $93.6 million in the prior quarter.
• Across five years, Operating Leases topped out at $137.4 million in Q2 2022 and bottomed at $74.9 million in Q4 2024.
• The 5-year median for Operating Leases is $95.5 million (2025), against an average of $98.1 million.
• Across the five-year window, Operating Leases surged 79.72% in 2022 and dropped 28.8% in 2025, its largest moves.
• Year by year, Operating Leases stood at $100.9 million in 2022, then slipped by 3.21% to $97.6 million in 2023, then fell by 23.23% to $74.9 million in 2024, then advanced by 24.87% to $93.6 million in 2025, then fell by 3.75% to $90.1 million in 2026.
• Per Business Quant, the three latest PTCT Operating Leases figures stand at $90.1 million (Q1 2026), $93.6 million (Q4 2025), and $95.5 million (Q3 2025).